354 reports of this reaction
2.1% of all PYRAZINAMIDE reports
#11 most reported adverse reaction
HEPATOTOXICITY is the #11 most commonly reported adverse reaction for PYRAZINAMIDE, manufactured by ANI Pharmaceuticals, Inc.. There are 354 FDA adverse event reports linking PYRAZINAMIDE to HEPATOTOXICITY. This represents approximately 2.1% of all 17,268 adverse event reports for this drug.
Patients taking PYRAZINAMIDE who experience hepatotoxicity should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEPATOTOXICITY is a less commonly reported adverse event for PYRAZINAMIDE, but still significant enough to appear in the safety profile.
In addition to hepatotoxicity, the following adverse reactions have been reported for PYRAZINAMIDE:
The following drugs have also been linked to hepatotoxicity in FDA adverse event reports:
HEPATOTOXICITY has been reported as an adverse event in 354 FDA reports for PYRAZINAMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEPATOTOXICITY accounts for approximately 2.1% of all adverse event reports for PYRAZINAMIDE, making it a notable side effect.
If you experience hepatotoxicity while taking PYRAZINAMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.